6533b7d8fe1ef96bd126a3e1
RESEARCH PRODUCT
Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions
Ansgar W. LohseMatthias TheobaldGiancarlo MaccagnoJürgen BurgGerd OttoPeter R. GalleStefan LüthEdite Antunes FerreiraM. SchuchmannCarl C. SchimanskiMarkus F. NeurathJürgen KuballGeorg HessAndreas SchwartingAna Paula Barreirossubject
medicine.medical_specialtyAdoptive cell transferLymphocytemedicine.medical_treatmentGraft vs Host Diseasechemical and pharmacologic phenomenaLymphocyte ActivationImmunotherapy AdoptiveSeverity of Illness IndexOrgan transplantationBlood Transfusion AutologousmedicineHumansAgedTransplantationbusiness.industryImmunotherapymedicine.diseaseAdoptive TransferLiver TransplantationTransplantationsurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureLymphocyte TransfusionImmunologyFemaleStem cellEpidermolysis BullosabusinessEx vivodescription
Background Prolonged persistence of donor-derived T cells after organ transplantation has been proposed to improve long-term allograft survival. However, surviving transplant-derived T cells are also able to mediate devastating graft-versus-host disease (GvHD). Currently, GvHD after organ transplantation is usually refractory to conventional therapy and the disease outcome fatal. Methods Graft-reactive host T cells were generated ex vivo from a patient suffering from a severe and refractory liver-transplant-associated GvHD. To control GvHD, activated alloreactive host T cells were repetitively retransferred into the patient (activated host lymphocyte infusion [aHLI]). Results Adoptive transfer of ex vivo activated alloreactive host T cells (aHLI) led to the control and complete resolution of severe GvHD without inducing allograft rejection. Conclusions aHLI opens a novel therapeutic window to control solid-organ transplant-associated GvHD while preserving allograft integrity.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2004-12-23 | Transplantation |